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Advance care planning (ACP) is a process of reflection and communication of a person’s 
future health care preferences, and has been shown to improve end-of-life (EOL) care 
for patients. The aim of this systematic review is to present an evidence-based over-
view of ACP in patients with primary malignant brain tumors (pmBT). A comprehensive 
literature search was conducted using medical and health science electronic databases 
(PubMed, Cochrane, Embase, MEDLINE, ProQuest, Social Care Online, Scopus, and 
Web of Science) up to July 2016. Manual search of bibliographies of articles and gray 
literature search were also conducted. Two independent reviewers selected studies, 
extracted data, and assessed the methodologic quality of the studies using the Critical 
Appraisal Skills Program’s appraisal tools. All studies were included irrespective of the 
study design. A meta-analysis was not possible due to heterogeneity amongst included 
studies; therefore, a narrative analysis was performed for best evidence synthesis. 
Overall, 19 studies were included [1 randomized controlled trial (RCT), 17 cohort studies, 
1 qualitative study] with 4686 participants. All studies scored “low to moderate” on the 
methodological quality assessment, implying high risk of bias. A single RCT evaluating 
a video decision support tool in facilitating ACP in pmBT patients showed a beneficial 
effect in promoting comfort care and gaining confidence in decision-making. However, 
the effect of the intervention on quality of life and care at the EOL were unclear. There 
was a low rate of use of ACP discussions at the EOL. Advance directive completion rates 
and place of death varied between different studies. Positive effects of ACP included 
lower hospital readmission rates, and intensive care unit utilization. None of the studies 
assessed mortality outcomes associated with ACP. In conclusion, this review found some 
beneficial effects of ACP in pmBT. The literature still remains limited in this area, with lack 
of intervention studies, making it difficult to identify superiority of ACP interventions in 
pmBT. More robust studies, with appropriate study design, outcome measures, and 
defined interventions are required to inform policy and practice.
Keywords: advance care planning, end-of-life care, communication, glioma, brain tumor
Abbreviations: ACP, advance care planning; AD, advance directive; BT, brain tumors; CASP, Critical Appraisal Skills Program; 
EOL, end-of-life; GBM, glioblastoma multiforme; pmBT, primary malignant brain tumor; QOC, quality of care; QoL, quality 
of life; WHO, World Health Organization.
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iNTRODUCTiON
Primary brain tumors (BT) are a diverse group of neoplasms, 
affecting approximately 7 persons per 100,000 population annu-
ally worldwide (1). Primary BT predominantly are malignant 
gliomas, and half of these are glioblastoma multiforme (GBM) 
(1). The diagnosis of primary malignant brain tumor (pmBT) 
heralds a dramatic change in life expectancy for patients, with 
limited effective treatment options, progressive neurological dete-
rioration, and high mortality rates. Despite advances in available 
therapies, GBM patients have a median survival of approximately 
14 months only (2). Many pmBT patients experience ongoing dif-
ficulties related to the disease itself with high symptom burden 
(3, 4), and treatments used. They also experience other disabilities, 
such as fatigue, difficulties with mobility and self-care, cognitive 
and intellectual decline, behavioral dysfunction, personality 
changes, and psychological problems, such as depression and 
anxiety. There are significant implications of these disabilities on 
caregivers with role reversal within families, vocational issues, 
financial strain, and reduced quality of life (QoL) (5, 6).
The neuropalliative supportive care needs of pmBT patients 
had previously been recognized and national guidelines acknowl-
edged ongoing considerable gaps in provision of end-of-life (EOL) 
care, including earlier Advance Care Planning (ACP) discussions 
for those with terminal conditions (7–9). ACP is the ongoing 
process that involves decisions made by patients, in consultation 
with surrogate decision-makers, family and health care providers 
regarding their values, beliefs, life-sustaining treatment prefer-
ences, goals of care (GOC), and palliative care options, should 
they later become incapable of expressing such wishes. ACP 
may further include the patient completing an advance directive 
(AD) which documents his or her wishes and/or appointment of 
a substitute decision-maker.
Advance care planning is recognized as an important element 
in improving EOL care, and one that is increasingly used in an 
international context because it allows patients to direct their own 
ongoing care. This contributes to shared decision-making, result-
ing in enhanced QoL for the patient. ACP has also been shown 
to increase patient and family satisfaction with EOL care (10, 11) 
and improve understanding and compliance between physicians 
and family members with patients’ wishes for EOL care (10, 12). 
In addition, ACP increases the likelihood of a person dying in his 
or her preferred place (13), increases hospice use, and reduces 
hospitalization, with lower stress levels, anxiety, and depression 
in surviving relatives (10, 11).
Discussing EOL issues with pmBT patients is especially chal-
lenging. The rapidity of cognitive decline due to tumor growth, 
tumor-related seizures or treatment effects (14) often precludes 
the expression of future wishes and treatment preferences, 
leaving families and clinicians to decide whether and when to 
withdraw interventions after patients have lost capacity to decide 
for themselves. Furthermore, delirium, dysarthria, dysphasia, 
and personality changes are also common (3, 8), which may 
lead to impaired communication about complex topics, such as 
hydration, nutrition, steroid interruption, and palliative sedation 
(3). Many often have limited understanding of their treatment 
options, and prognostic uncertainty impacting on this process, 
resulting in difficulty achieving realistic expectations and deter-
mining appropriate treatment decisions (15). Cultural, religious 
and spiritual factors also tend to play a role in EOL decision-
making. Many clinicians often avoid the topic in practice due 
to time pressures, lack sufficient communication skills training, 
and are uncertain about timing and content of ACP with fear of 
upsetting patients (16).
Advance care planning has been widely explored in the litera-
ture in different patient cohorts, including cancer, chronic renal 
failure, heart failure, chronic obstructive pulmonary disease, and 
other life-limiting conditions. A number of studies had previ-
ously investigated ACP in the BT cohort (17, 18). The body of 
research in this area is growing; however, published studies vary 
in methodology, scope, and interventions with different findings 
and conclusions. The outcomes following ACP interventions need 
to be established. However, to date, there is no systematic review 
evaluating ACP in pmBT patients to guide clinicians in ACP 
implementation. Therefore, the aim of this study is to systemati-
cally evaluate the current evidence and efficacy of ACP in pmBT 
patients to assist treating clinicians, and to ensure that services 
and supports are directed appropriately in this population.
MeTHODS
An integrated approach was employed, which included a com-
prehensive review of literature (peer review and gray literature), 
using medical and health science electronic databases (PubMed, 
Cochrane, Embase, MEDLINE, ProQuest, Social Care Online, 
Scopus, and Web of Science) up to July 2016. Bibliography search 
of identified articles and manual search of relevant journals for 
additional references were conducted. A further gray literature 
search was conducted using different internet search engines and 
websites, such as the PQDT Open, OATD, and Google Scholar. In 
addition, various healthcare institutions; and governmental and 
non-governmental organizations associated with management of 
individuals with pmBT were also explored for relevant studies. 
Authors and known experts in the field were contacted.
The search strategy used Medical Subject Headings (MeSH) or 
equivalent key words relating to pmBT and ACP. Premutations 
of the following search terms were truncated and exploded: 
brain cancer, neoplasm or malignancy, ACP, ADs, EOL com-
munication, life-sustaining treatment preferences, EOL decision-
making, EOL care, and living will. All unpublished studies and all 
trials registered in relevant registries were scrutinized to reduce 
publication bias.
inclusion and exclusion Criteria
A protocol for searching was established prior to commencement 
of the search. ACP was defined as “any advance discussions or 
directives pertaining to patients’ life-sustaining treatment prefer-
ences, goals of care, palliative care options, appointment of a health 
care proxy and may further include the completion of an AD” 
(19). Inclusion criteria were determined as follows: (1) articles 
published in peer-reviewed journals, irrespective of study design; 
(2) studies with participants with confirmed diagnosis of pmBT 
[also specified as malignant glioma, high-grade glioma (HGG), 
anaplastic astrocytoma, GBM, anaplastic oligodendroglioma, 
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oligoastrocytoma or World Health Organization (WHO) tumor 
grades III and IV]; and (3) 18  years and above. Other studies 
conducted in different patient cohorts were also included if they 
provided data for >50% of pmBT patients.
Articles were excluded if the participant subgroups with pmBT 
were not clearly defined. Theses, narrative reviews, editorials, 
case reports/series, and published conference abstracts were also 
excluded.
Study Selection and Data extraction
Two authors (Krystal Song and Fary Khan) independently 
screened all identified study titles and abstracts for inclusion 
based on the selection criteria. Any disagreements were resolved 
by consensus discussion with the third author (Bhasker Amatya). 
Preliminary synthesis was conducted by using a standard pro 
forma created a priori with data extraction from studies, which 
included study characteristics (publication year and country, 
study type, sample characteristics, methodology, outcome meas-
ures, key findings) and intervention characteristics where feasible 
[type, intensity, domain, setting, delivery mode, duration and any 
information available about training and feasibility (e.g., adher-
ence)]. Additional description of interventions was obtained 
from the study corresponding author where necessary.
Thematic analysis of the primary findings presented by each 
study was undertaken. Findings were individually scrutinized by 
the two authors (Krystal Song and Fary Khan), who discussed, 
extracted, and refined key emergent themes. Final themes were 
then developed and reviewed with feedback sought from the 
third author (Bhasker Amatya). Any disagreements were resolved 
by group discussions.
Two authors (Krystal Song and Bhasker Amatya) indepen-
dently assessed the methodologic quality and grade of evidence 
of included studies with the CASP tool (20). The CASP tool 
uses a systematic approach to appraise different study designs 
from the following domains: study validity, methodologic 
quality, presentation of results, and external validity (20). The 
articles were graded independently, and any disagreements were 
resolved through consensus. Each of the items from the check-
lists were judged with “yes” (low risk of bias, score 1), “no” (high 
risk of bias), or “cannot tell” (unclear or unknown risk of bias, 
score 0). Total scores were used to grade the methodologic qual-
ity of each study assessed [maximum score 11 for randomized 
controlled trial (RCTs); 12 for cohort studies; 10 for qualitative 
studies] (20).
ReSULTS
Results of the Search
The combined searches retrieved a total of 2177 published titles 
and abstracts, of which 1838 were screened after removal of 
duplicates. Seventeen articles met inclusion criteria for analysis. 
Further citation and journal hand searches identified two articles 
that were included for final analysis. In total, 19 articles (1 RCT, 17 
cohort studies, 1 qualitative study) were determined as eligible for 
this systematic review. See Figure 1 for a PRISMA flow diagram 
of the study selection process.
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Study Characteristics
The included studies were conducted in different countries: three 
each were conducted in the USA, Italy, and Australia; two each in 
Germany, Austria, Netherlands, and UK, while two studies were 
multicentered and conducted in three different countries: The 
Netherlands, Austria, and UK. The included studies evaluated a 
total of with 4686 participants. Detailed information regarding 
the included studies is presented in Table 1. Only one randomized 
controlled trial (RCT) was identified which evaluated a video 
decision support tool on ACP in pmBT patients (17). Other were 
observational studies, including 14 retrospective and 3 prospec-
tive cohort studies and 1 was a qualitative study.
Study Quality Assessment
There was consensus agreement amongst reviewers regarding 
methodology used in the studies. Table  2 provides a qual-
ity assessment of included studies using the CASP tool (20).
The methodologic quality of included studies varied. The only 
included RCT was of moderate quality (CASP  =  8/11). This 
study was, however, underpowered and had insufficient blind-
ing procedures (17). The CASP scores for the 17 cohort studies 
ranged from 2 to 7 out of 12. The overall quality of most included 
cohort studies was assessed as low to moderate, of which eight 
studies were of moderate quality (3, 21, 22, 25, 28, 30, 32, 33). All 
cohort studies had substantial flaws in methodologic design with 
a high risk of bias related to heterogeneous patient characteristics, 
study design, and outcome analysis. Outcome measurement tools 
varied among studies, and some tools used were not validated.
Synthesis of Results
Pooling of data was not possible due to heterogeneity among the 
included studies in terms of study design, interventions used and 
presentation of findings. Therefore, study findings are described 
narratively in most relevant subheadings.
Description of ACP Interventions
In a RCT, El-Jawahri et al. evaluated the feasibility and effective-
ness of a video GOC decision support tool in facilitating ACP in 
pmBT patients (17). This video tool was used to supplement a 
verbal description in aiming to improve EOL decision-making 
in pmBT patients. Fifty participants were randomly assigned to 
either the verbal narrative (n = 27) or additional video tool after 
the verbal narrative (n = 23). The findings suggested that the video 
tool was effective in promoting comfort care and gaining confi-
dence in decision-making compared to verbal description only. 
No participants in the video tool group preferred life-prolonging 
care, 4.4% preferred basic care, 91.3% preferred comfort care, and 
only 4.4% were uncertain (p < 0.0001), while in participants in 
the verbal narrative group, 25.9% of participants preferred life-
prolonging care, 51.9% basic care, and 22.2% comfort care (17). 
However, the effect of the video intervention on QoL and care at 
the EOL were unclear. This study was underpowered with small 
sample size and has methodological flaws such as lack of blinding 
of assessors (17).
Another intervention study assessed the impact of a pilot 
program of comprehensive palliative care (including the provi-
sion of palliative ACP) for pmBT patients on place of death 
(POD), rehospitalization rate in the last months of life, and the 
cost-effectiveness of the care model (30). Of the 529 patients who 
died, 61% were assisted at home until the EOL, 22.2% died in 
hospital, and 16.8% died in inpatient hospice. Hospitalization 
readmission rates and intensive care unit utilization in the last 
2 months of life in a subgroup of GBM patients assisted by the 
home care program were significantly lower than the control 
group who did not receive home assistance (16.7 vs. 38%, respec-
tively; p < 0.001) (30). The authors, however, failed to report the 
impact of palliative home care program on QoL, quality of dying 
or caregiver burden.
Prevalence and Preference for Timing and Content of 
EOL Discussions
End-of-life discussions were poorly used in the included stud-
ies. Two studies reported that approximately 12–40% of pmBT 
patients did not have EOL discussions involving decisions 
regarding treatment preferences, health care proxy (HCP), pal-
liative care consultation, hospice discussion, and resuscitation 
wishes (18, 25).
Gofton et  al. retrospectively evaluated timing and content 
of EOL discussions in pmBT patients who were admitted to 
hospital within 6 months of death (25). The authors found that 
of 43 deceased pmBT patients, potential admission to a hospice 
was discussed in 38 patients (88%), a HCP was appointed in 33 
patients (77%) and 28 patients (65%) had a do-not-resuscitate 
(DNR) order. Hospice discussions were initiated at a median of 
39 days before death, and DNR orders were filled in at a median of 
41 days before death. There was a wide degree of variation in the 
timing of EOL discussions such as hospice planning (1–140 days) 
prior to death and resuscitation wishes (1–140 days) (25). Overall, 
discussions about treatment restrictions in pmBT patients were 
often initiated relatively close to death (25). Common EOL 
treatment decisions also concern hydration (87%), comfort care 
(82%), steroid interruption (45%) tube feeding (13%), palliative 
sedation (13%), and ADs (6%) (30).
AD Completion Rates and Nomination of Health Care 
Proxy
Rates of AD completion varied widely between countries. In a 
study examining EOL care in HGG patients conducted in three 
European countries, the authors reported significant contrast in 
written AD completion, including 46% in Dutch, 37% in British, 
and only 6% in Austrian patients (p < 0.001) (28). Overall, the 
findings from the included studies in this review showed that 
around 0–76% of pmBT patients had an AD completed (3, 5, 17, 
18, 23, 26, 28, 30, 31, 34). The nomination of health care proxies 
ranged from 8 to 77% among the studies (3, 22, 26).
Use of Palliative Care and Hospice, and Place of 
Death
The use of palliative care in pmBT is widely discussed in the 
included studies (3, 21, 24, 25, 27, 30, 31, 33). Collins et al. exam-
ined the clinical presentation and patterns of care for short-term 
pmBT survivors (21). The authors found that 22% of short-term 
survivors (those who died during initial admission) did not have 
contact with palliative care. Of the 23% (n = 264) of patients who 
TABLe 1 | Summary of included studies.
Reference, 
country
Aim of study Study type Methodology Participants and demographic 
characteristics
Key findings
1. Arber et al. (6), 
UK
To investigate symptom 
profile and access 
to rehabilitation and 
supportive care services 
of primary malignant 
brain tumor (pmBT) 
patients and carers
Retrospective 
cohort study
Data collected included demographic 
information, symptom profile, care issues, 
services used, and place of death (POD)
N = 70 79% (n = 55) had details of POD including 30% who 
died at hospice, 16% at home, 20% in another hospital, 
13% nursing home
Mean age 64 years (range 21–94); 
women 44%; glioblastoma 
multiforme (GBM) 59%
2. Collins et al. 
(21), Australia
To investigate the 
clinical presentation, 
patterns of supportive 
and palliative care (PC) 
utilization for short-
term malignant glioma 
patients (survival time 
<120 days)
Retrospective 
cohort study
Retrospective cohort study of incident malignant 
glioma cases between 2003 and 2009 surviving 
<120 days in Victoria, Australia. Data collected 
included clinical symptoms, hospital utilization, 
supportive care utilization, PC involvement, and 
POD
N = 482 (no. of shorter term 
survivors of total 1,160 patients 
with incident PMG diagnosis)
62% of Group 1 was admitted to a PC bed during the 
diagnosis admission. 22% of the cohort died without 
any PC contact
Group 1 (n = 218, 19%) died 
during diagnosis admission; 89% 
GBM; mean number of hospital 
bed days = 40 (median 33)
Group 2 (n = 264, 23%) survived 
the diagnosis admission but died 
within 120 days from diagnosis; 
86% GBM; mean number of 
hospital bed days = 17 (median 11); 
POD: home 32%, PC bed/hospice 
38%, and acute hospital 30%
Only 12% of Group 2 patients had a PC consultation for 
appropriate planning and support during their diagnosis 
admission as compared to 78% of group 1 patients
3. Diamond et al. 
(22), USA
To evaluate the 
frequency of and 
characteristics 
associated with early 
vs. late hospice referral 
in pmBT patients
Retrospective 
cohort study
Data collected included demographic data, 
presence of health care proxy (HCP), clinical 
characteristics and utilization of homecare 
services, and characteristics associated with late 
vs. earlier referral to home hospice
N = 160 Of 160 patients with pmBT followed to death in hospice 
care, 32 (22.5%) were enrolled within 7 days of death. 
In comparison to early hospice referral, a greater 
proportion was bedbound at admission (97.2 vs. 
61.3%), aphasic (61.1 vs. 20.2%), unresponsive (38.9% 
vs. 4%) or dyspneic (27.8% vs. 9.7%). Male patients, 
Medicaid insurance coverage and those without a HCP 
were significantly associated with late referral. 36% 
(n = 58) of all patients had no appointed HCP at time 
of home hospice admission. 55.6% (n = 20) of those 
referred late to hospice did not have a HCP
Mean age 63.4 years (SD, 15.6); 
women, 42%; 65% GBM; POD: 
home 82%, affiliated hospice 
facility 18%
4. El-Jawahri et al. 
(17), USA
To evaluate the 
effectiveness of the use 
of goals-of-care (GOC) 
video to supplement 
a verbal description in 
improving end-of-life 
(EOL) decision-making 
for malignant glioma 
patients
Randomized 
controlled trial
50 participants with malignant glioma were 
randomly assigned to either a verbal narrative 
of GOC options at the EOL (control) (n = 27), 
or a 6-min video after the same verbal narrative 
(intervention) (n = 23)
N = 50
Mean age, 54 years; range, 
32–77 years; 44% women; 82% 
married; 76% had an advance 
directive (AD); 72% GBM
After verbal description, 25.9% of participants’ 
preferred life-prolonging care, 51.9% basic care and 
22.2% comfort care. In the video arm, no participants 
preferred life-prolonging care, 4.4% preferred basic 
care, 91.3% preferred comfort care, and 4.4% were 
uncertain (p < 0.0001). The mean increase in knowledge 
score was higher in the video group compared to the 
verbal control group (1.9 vs. 0.9; p = 0.004). The mean 
uncertainty score regarding decision-making (range, 
3–15; higher score indicating less uncertainty) was higher 
in the video group than in the verbal group (13.7 vs. 
11.5, respectively; p < 0.002). 82.6% in the intervention 
arm reported being very comfortable watching the video
Primary outcome measure: post-intervention 
preference for EOL care
Secondary outcome measures: change in 
knowledge scores after the narrative or video; 
decisional conflicts scores between both 
interventions
(Continued)
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Reference, 
country
Aim of study Study type Methodology Participants and demographic 
characteristics
Key findings
5. Faithfull et al. 
(23), UK
To explore the 
referral and carer 
characteristics, illness 
trajectory, symptoms 
and services provided 
to carers and patients 
with pmBT referred 
to PC
Retrospective 
cohort study
Data collected included demographics, PC, 
service utilization, symptom profile and time from 
diagnosis of brain tumor to referral and death
N = 39 Out of 37 who died, POD: 33% (n = 13) home, 33% 
(n = 13) hospice, 13% (n = 5) nursing home
6. Flechl et al. (24), 
Netherlands
To evaluate the 
caregivers’ experiences 
on the EOL phase of 
deceased GBM patients
Retrospective 
questionnaire 
completion by 
caregivers
Data collected included the caregiver’s view 
of the patients’ terminal phase, experiences 
and emotions of caregiver during the last three 
months of patients’ life, patients’ quality of life 
(QoL), quality of care, EOL preferences and POD 
information
N = 52. 30/52 patients had expressed preferences for their 
place of death; 79% wished to die at home and 68% of 
them fulfilled this. No patient had expressed a formal AD
Mean age, 63 years; range, 
35–83 years; women, 37%; POD: 
home 40%, hospice 12%, hospital 
46%, and nursing home 2%
7. Gofton et al. 
(25), USA
To evaluate the PC 
needs and EOL 
decisions of patients 
with primary and 
metastatic brain tumors
Retrospective 
cohort study
Data collected included evidence of resuscitation 
at the EOL, evidence of cancer directed therapy 
in the last month of life, HCP, PC consultation, 
hospice discussion, and evidence of discussion 
regarding resuscitation wishes
N = 168 (total sample) including 
primary BT (n = 144) or metastatic 
brain tumor (n = 24)
Of the WHO grade III/IV brain tumor patients who died 
during the course of the study (n = 43), approximately 
12% had no documented EOL discussions, 76.7% had 
an appointed HCP, and 65.1% had a do-not-resuscitate 
order. The timing of EOL discussions to death such as 
hospice planning (1–140 days) (median = 28 days) and 
resuscitation wishes (1–140 days) (median = 31.5 days) 
varied widely
Grade III/IV glial tumors: N = 101 
(70.1% of primary brain tumor 
sample); Mean age, 58.2 ± 15, 
42 (41.6%) women; 43 (42.6%) 
deceased; POD (n = 43): home 
20.9%, outpatient hospice support 
34.9%, hospice 32.6%, and 
nursing home 2.3%
8. Golla et al. (26), 
Germany
To evaluate whether 
GBM patients are 
capable of regular 
self-assessment of 
their symptoms and 
needs during disease 
progression
Prospective 
cohort study
GBM patients’ PC issues were assessed from 
diagnosis to death or for at least 12 months 
every 7 weeks (±8 days). Each assessment 
consisted of two parts: (1) semi-structured 
interview regarding current disease status, 
treatment, burdensome symptoms, EOL care 
wishes; (2) PC assessments using the Hospice 
and Palliative Care Evaluation (HOPE, 27 items) 
and the Palliative Outcome Scale (POS, 11 items)
N = 13 31% of patients in this study obtained AD during the 
course of GBM disease, and 62% obtained HCPs. 
Repeated interviews in the current study may have 
possibly influenced GBM patients’ ACP
Age range, 45–71 years; women, 
31%; 15% (n = 2) AD, 8% (n = 1) 
HCP; POD: home 23%, hospice 
31%, nursing home 8%, and 
hospital 38%
9. Heese et al. (27), 
Germany
To evaluate caregivers’ 
perception of medical 
and psychological 
support received during 
the final disease phase 
of glioma patients
Retrospective 
cohort study
Data collected from caregivers through 
questionnaires included patients’ place of PC 
during final 4 weeks and POD, supporting 
physician, medical support for EOL problems, 
receipt of counseling by physician with regards 
to PC 
N = 605 Medical support was provided by GPs in 72.3% of 
cases, 29.9% by physicians affiliated with a nursing 
home or hospice, 17% by general oncologists and 6% 
by specialized neurooncologists. 21.3% of patients 
received care from physicians who specialized in PC 
medicine
WHO Grade IV tumor 71.3% 
(n = 398); mean age 58.8 years 
(range 17.6–86.7 years) (total 
sample); POD: home 47.7%, 
hospice 19.3%, nursing home 
7.3%, and hospital 22.6%
(Continued)
TABLe 1 | Continued
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10. Koekkoek 
et al. (28), 
Netherlands, 
Austria, UK
To evaluate cross-
national differences 
whether different 
patterns of EOL care 
meet patient’s specific 
needs
Retrospective 
cohort study 
Data collected from relatives of deceased pmBT 
patients examined: (1) EOL care organization 
such as place of care, transitions to another 
health care setting, and POD; (2) treatment 
preferences, including presence of AD and 
preferred POD; (3) experiences with EOL care: 
actual POD, quality of information provided by 
treating physician, satisfaction with explanation 
of treatment decisions and symptoms treatment; 
and (4) perceived quality of care (QOC) during 
last 3 months before death
N = 207
Total number of patient’s relatives 
who could be traced: Dutch 
(n = 131), Austrian (n = 119) 
and British (n = 89). Returned 
questionnaires included 83 (63%) 
Dutch, 72 (61%) Austrian, and 52 
(58%) British relatives
Three months before death, 75% of patients were at 
home. POD differed significantly (p < 0.001). In the 
Netherlands, Austria and UK, respectively, patients most 
often died at home (60%), in a hospital (41%) or hospice 
(41%) (p < 0.001). Three months before death, patients 
expressed specific treatment wishes to their relatives in 
almost 80% in Dutch population, in contrast to 58 and 
48% of Austrian and British patients (p < 0.001)
Written AD was used in 46% of Dutch, 37% of British, 
but only 6% of Austrian patients (p < 0.001). In 10% 
of patients, physicians made decisions that were 
incongruent with patient’s earlier expressed preferences, 
irrespective of country. Dying at the preferred place, 
satisfaction with information provided and effective 
symptom treatment were independently associated with 
good QOC
11. Koekkoek 
et al. (29), 
Netherlands, 
Belgium, Austria
To evaluate prevalence 
of symptoms 
and medication 
management in pmBT 
patients during EOL 
phase
Retrospective 
cohort study
Data collected included symptoms, general EOL 
symptoms, perceived QOC
N = 178 POD included home 54.7%, hospice 18.2%, hospital 
12.4%, nursing home 12.4%Mean age 59.7 years; women 
29.8%; Grade IV brain tumor 
89.3%
12. Pace et al. (3), 
Italy
To explore EOL issues 
and treatment decisions 
in a population of brain 
tumor patients followed 
at home until death by a 
neuro-oncologic home 
care palliative unit
Retrospective 
cohort study
Patients were enrolled in a comprehensive 
program of neuro-oncological home care, 
receiving neurological assistance, nursing, 
psychosocial support, and rehabilitation at home. 
Data collected included clinical symptoms, PC 
treatments, and EOL treatment decisions
N = 169 Only 6% had early AD about EOL treatment. Majority 
were not competent to make treatment decisions in the 
last month of life. Tube feeding was installed in 13% 
of patients, steroids tapered in 45% of patients and 
palliative sedation in 13% of patients. Only 52.9% of 
patients were fully aware about prognosis, 27% partially 
aware, and 20% unaware
Mean age, 56 years; range, 
15–93 years; women, n = 87; 
79.9% GBM
13. Pace et al. (30), 
Italy
To evaluate a pilot 
neuro-oncological 
home care program of 
comprehensive palliative 
care for brain tumor 
patients
Retrospective 
cohort study
This model aimed to meet patients’ needs for 
care in all stages of disease, support the families 
and reduce the rehospitalization rate. The intensity 
of care changes in different stages of disease from 
low intensity (e.g., home visit, phone contact) to 
medium level intensity in the disease progression 
stage [more than one weekly visit, nursing 
assistance, psychological assistance, palliative 
advance care planning (ACP), and high intensity in 
the EOL stage (e.g., 3 weekly home visits)].
N = 848
Male/female ratio 439:409; mean 
age 57 years (range: 17–89 years); 
50.1% GBM
Of the 529 patients who died, 
323 (61%) were assisted at home 
until the EOL, 117 (22.2%) died in 
hospital, and 89 (16.8%) died in 
hospice
Common EOL treatment decisions in 323 BT patients 
who were assisted at home until death included steroid 
withdrawal (45%), mild hydration (87%), tube feeding 
(13%) and palliative sedation (11%). Only 6% of these 
patients had an AD
Cost-effective analyses performed in a subgroup of 
GBM patients showed that a group of patients assisted 
by the home care program (n = 72) had significantly 
lower hospital readmission rates and ICU utilization in 
the last 2 months of life than the control group (n = 72), 
who did not receive home assistance (16.7 vs. 38%, 
respectively; P < 0.001). There was also a statistically 
significant difference in economic cost for care delivered 
during hospital stays in the same period ($9990 vs. 
$76,000; p < 0.001)
Data analyzed included POD, caregiver 
satisfaction, rehospitalization rate and the impact 
on costs to the health system
(Continued)
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Reference, 
country
Aim of study Study type Methodology Participants and demographic 
characteristics
Key findings
14. Pompili et al. 
(31), Italy
To evaluate the results 
of home PC and EOL 
issues in GBM patients 
Retrospective 
cohort study
The intensity of the home care program ranged 
from low intensity (weekly home access or contact 
by phone standard ambulatory consultation) to 
a medium level of intensity in patients with more 
progressive stage (more than one weekly access, 
nursing assistance, psychological assistance, 
palliative ACP) and a high level of intensity of care 
in the EOL stage (at least 3 weekly accesses)
N = 122 Only 6% of patients in this study had an AD
100% GBM patients; 52.4% 
died (n = 64), median survival 
13.34 months; POD: home 53.1%, 
hospice 34.4%, and 12.5% 
hospital
15. Sizoo et al. (32), 
Netherlands
To evaluate the 
proportion of pmBT 
patients dying with 
dignity as perceived by 
their relatives; to identify 
disease and care 
factors correlated with 
dying with dignity
Retrospective 
survey of 
carers’ 
perspectives
Data collected included patients’ symptom 
profile, health-related QoL, decision-making, 
place and quality of EOL care, and dying with 
dignity
N = 81 75% of relatives of patient cohort indicated that the 
patient died with dignity. These patients had fewer 
communication deficits, fewer transitions between 
health care settings in EOL phase and more frequently 
died at preferred POD. Higher satisfaction rates with 
the physician, the ability to communicate EOL decisions 
and absence of transitions between settings were most 
predictive of a dignified death. Patients who died at 
home died most often with dignity (83%), followed by 
hospice (71%), hospital (63%), and nursing home (50%) 
patients (p = 0.255)
Mean age at death, 61 years; 
range, 20–86 years; women, 36%; 
POD: home 57%, hospice 17%, 
nursing home 12%, and hospital 
10%
16. Sizoo et al. (18), 
Netherlands
To evaluate the EOL 
decision (ELD) making 
process in high-grade 
glioma (HGG) patients
Retrospective 
cohort study
Questionnaire data collection from physicians 
and relatives regarding EOL conditions (patients’ 
ELD preferences, patients’ competence) 
and ELD-making (forgoing treatment and the 
administration of drugs with a potential life-
shortening effect)
N = 101 Of 101 patients, there was a 62% (n = 51) 
physician response rate, with relatives’ data for 
an additional 50 patients. 52% of patients were 
relatively incompetent to make decisions due to EOL 
cognitive deficits. 40% of patients did not have EOL 
preference discussions with their physician. Only 
3% of patients declined this discussion. At least 
one EOL decision was made in 72% of patients, 
most often steroid withdrawal. In a subset of 
deceased patients (n = 50), 42% of patients had an 
AD, with 4% of physicians not being aware of this. 
Incongruence existed between patients’ EOL wishes 
with physician decisions in EOL care
Mean age at death, 60 years; 
range, N/A; women, 28%; Grade 
4 HGG 88%, Grade 3 HGG 12%; 
POD: home 66%, hospice 10%, 
hospital 7%, and nursing home 
16%
17. Sundararajan 
et al. (33), 
Australia
To evaluate the 
association between 
symptoms, receipt of 
supportive and PC, and 
POD of pmBT cases 
who survived for at least 
120 days between their 
first hospitalization and 
death
Retrospective 
cohort study
Data collected included patient characteristics, 
receipt of supportive and PC, and POD. PC 
would include tasks of care education, clear 
information, emotional support and equipment 
access, carer support, exploration of preferences 
and informed decision-making
N = 678 Increased receipt of PC consultation from 5 to 
63% and the use of a hospice bed from 2 to 49% 
from diagnosis to hospitalization during which they 
died was shown. Patients having one or more 
symptoms were more than five times as likely to 
receive PC. Factors associated with POD were 
patients who received any PC in the last 120 days 
before death
Mean age 62y; women, 40%; 
median survival 11 months; GBM, 
84%; POD: home 26%, hospice 
49%, and acute hospital 25%
(Continued)
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survived the diagnosis admission but died within 120 days later, 
only 12% had a palliative care consultation for appropriate plan-
ning and support during their diagnosis admission. Surprisingly, 
the majority (38%) died in a palliative care bed/inpatient hospice, 
32% died at home, and 30% in an acute hospital (21). It was sug-
gested that timely referral to palliative care at the initial point 
of discharge may have facilitated death at home or in a more 
appropriate and cost-efficient hospital setting. This study was of 
retrospective design and did not evaluate other factors predicting 
shorter survival rates. In another study, Heese et al. retrospectively 
assessed the palliative care involvement in EOL support of pmBT 
patients and found that only 21.3% of patients received care from 
physicians who specialized in palliative medicine in their final 
4 weeks prior to death (27).
A study conducted in Australia found that pmBT patients 
who received any palliative care in the last 120 days before death 
were more likely to die out of hospital (25). Pace et al. evaluating 
a pilot program of comprehensive palliative neurological home 
care for BT patients (30), showed a subgroup of GBM patients 
(n = 425) who were assisted by the palliative home care program 
had significantly lower hospital readmission rates, ICU utiliza-
tion in the last 2 months of life compared to the control group 
who did not receive home assistance (16.7% vs. 38% respectively; 
p < 0.001) (30).
Similarly, there was variability in the reported POD among dif-
ferent countries. Study findings suggested that the reported rate of 
dying at home were 21–82% in USA (22, 25), 26–32% in Australia 
(21, 33), 40–66% in The Netherlands (5, 18, 28, 29, 31, 32), 53–65% 
in Italy (3, 30, 31), 16–33% in UK (6, 24), and approximately 
23–48% in Germany (26, 27). Overall, approximately 8–33% of 
pmBT patients were reported dying in inpatient hospice (5, 21, 
27–31, 33) or with affiliated hospice support (22, 25).
Patient/Surrogate Confidence and Congruence in 
EOL Decision-Making
Patient confidence in ACP decision-making was shown to be 
associated with various factors. El-Jawahri et al. in a RCT showed 
that patient confidence in EOL decision-making and ACP 
increased when a video support decision-making tool was used 
(17). The mean uncertainty score regarding decision-making 
(range, 3–15; higher score indicating less uncertainty) was sig-
nificantly higher in the intervention group (with additional video 
support) compared to controls with verbal support only (13.7 vs. 
11.5; p < 0.002) (17), with video arm participants significantly 
preferring comfort care (p < 0.0001). Approximately 82.6% in the 
video intervention arm in this study reported being very comfort-
able watching the video (17).
Sizoo et  al. retrospectively assessed the patients’ relatives 
concerning EOL phase of pmBT patients involving health-related 
QOL, decision-making, place and quality of EOL care and dying 
with dignity (32). The authors found that higher satisfaction rates 
with the physician, fewer transitions between health-care settings 
in the EOL phase, ability to communicate EOL decisions, and 
more frequently dying at preferred POD were associated with a 
dignified death (32). This study, however, had various methodo-
logical flaws including retrospective design, proxy ratings with 
recall bias, and small sample size.
TABLe 2 | Levels of quality of individual studies (CASP approacha).
Randomized controlled trials
Study Clear 
focused 
issue
Adequate 
randomization 
procedure
Participants 
properly 
accounted
Blinding of 
participants/
assessors
Groups 
similar at 
start 
Groups 
treated equally
Large 
treatment 
effect
Precise 
treatment 
effect
Applicability 
of results 
to local 
population
Clinically 
important 
outcomes 
considered
Benefits 
worth harm 
and costs
CASP 
Grade
El-Jawahri et al. (17) + + + − − + + + + + ? 8/11
Cohort studies
Study Clear 
focused 
issue
Appropriate 
method
Appropriate 
cohort 
recruitment
exposure 
accurately 
measured
Outcome 
accurately 
measured
important 
confounding 
factors 
accounted
Adequate 
follow-up
Strong 
exposure 
and outcome 
relation
Precise 
results
Believe  
the  
results
Applicability  
of results 
of local 
population
Comparability 
of results with 
other available 
evidence
CASP 
Grade
Arber et al. (6) + + + − − − − − − − − − 3/12
Collins et al. (21) + + + + + − + − ? ? + ? 7/12
Diamond (22) + + + + + − ? + + ? − − 7/12
Faithfull et al. (24) + + + − − − − − − − − − 3/12
Flechl et al. (5) + + − − − − − − − − − − 2/12
Gofton et al. (25) + + + − − − + − + + − ? 6/12
Golla et al. (26) + + − − + + − ? ? ? − − 4/12
Heese et al. (27) + + + − − − ? − − − − − 3/12
Koekkoek et al. (28) + + + + − + ? + + − − − 7/12
Koekkoek et al. (29) + + + − − − − − − − − − 3/12
Pace et al. (30) + + + − − − + − − + − − 5/12
Pace et al. (30) + + + + − − + ? − − − − 5/12
Pompili et al. (31) + + + − − − − − ? − − − 3/12
Sizoo et al. (32) + + + − − + ? + + + − ? 7/12
Sizoo et al. (18) + + + − − − ? − − − − − 3/12
Sundararajan et al. 
(33)
+ + + + + − + − ? ? + ? 7/12
Thier et al. (34) + + + − − − − − − − − − 3/12
Qualitative studies
Study Clear 
statement 
of aims
Appropriate 
qualitative 
methodology
Appropriate 
research 
design
Appropriate 
recruitment 
strategy
Appropriate 
data 
collection
Relationship 
between 
researcher 
and 
participants
ethical issues 
taken into 
consideration
Sufficient 
data  
analysis  
rigor
Clear 
statement  
of findings
Research 
value
Song (23)b + + − − + − + − ? + 5/10
+, yes; −, no; ?, cannot tell.
Ratings: 8 or > out of 10: good quality; 5–7: moderate quality; <5: poor quality.
aCASP critical appraisal tool for qualitative research (20).
bAs this study was conducted by the author, critical appraisal of this study was performed by an independent reviewer (Professor Mary Galea).
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Various studies used congruence with patient wishes as an 
outcome measure. The findings suggested that completion of an 
AD is not often sufficient to ensure congruence with patients’ 
wishes for EOL care. In a study examining EOL care in pmBT 
patients in three European countries, physicians made decisions 
that were not in accordance with patients’ earlier expressed 
preferences, was reported in 10% of patients (28). The authors 
also found that the actual POD was in accordance with preferred 
POD only in 67% of Dutch, 56% of the Austrian and 39% of the 
British patients (p = 0.014), likely reflecting health care system 
differences toward EOL care (28).
Another retrospective survey of physicians in the Netherlands 
examining the EOL preferences of patients and congruence with 
physician decisions showed that in 40% of pmBT patients, physi-
cians were unaware of patients’ EOL preferences, even though 
several had an AD according to their relatives (18). The authors 
found that these preferences were related to life-prolonging 
treatment preferences, admission to hospital, palliative seda-
tion or euthanasia. The authors also indicated that there was 
incongruence between physician and patients’ EOL wishes with 
decisions made against patient’s wishes in a small proportion of 
patients (18).
Patient–Clinician Communication and Interaction 
Quality, Patient and Family Well-Being, QoL, and 
Satisfaction
Four studies found a significant beneficial effect of ACP on 
patient-clinician communication and interaction quality (28, 
30–32). Sizoo et  al. assessed the proportion of pmBT patients 
dying with dignity as perceived by their relatives (32). Factors 
most predictive of a dignified death included higher satisfac-
tion rates with the physician, the ability to communicate EOL 
decisions and the absence of transitions between healthcare 
settings (32). These findings were consistent with another cross-
national study comparing EOL care in pmBT patients in three 
European countries (28). Good quality of care (QOC) during the 
last 3 months prior to deaths was shown to be associated with 
effective treatment of physical symptoms and satisfaction with 
information provided (28). A home neuro-oncological palliative 
care program also had a positive impact on perception of QOC 
through communication and psychological support offering ACP 
and EOL care discussions perceived by caregivers (30, 31).
The review identified a limited number of studies examin-
ing the outcomes of ACP on patient or family well-being, QoL, 
and satisfaction. Caregiver QOL was generally rated low in the 
context of pmBT patients’ illness trajectory and this did not differ 
between caregivers of patients, who died at home (40%) or in 
hospital (46%) (5). One study examining the EOL phase of pmBT 
patients found that with those patients who died with dignity, 
EOL decisions were more often explicitly discussed and relatives 
were more satisfied with physician(s) providing EOL care (32). 
The authors report that pmBT patients who died most often with 
dignity were those who died at home (83%), compared to those 
who died in other health care settings including hospice (71%), 
hospital (63%), and nursing home (50%) (32). This study had 
some limitations due to retrospective design, recall bias based on 
relatives’ information and small sample size.
Hospital Utilization and Mortality Rates
Hospital utilization is frequently measured as an economic 
marker of health care costs. Hospital utilization in pmBT patients, 
in terms of POD, reported among the studies varied between dif-
ferent countries and ranged from 7 to 46% (5, 6, 18, 21, 26–33).
Two studies assessed hospital utilization as an outcome 
measure (21, 30). Collins et al. examined the patterns of care for 
shorter term survivors of pmBT patients in Australia (21). The 
authors divided these patients into Group 1 (19%, n = 218) (died 
during diagnosis admission), Group 2 (23%, n = 264) (survived 
diagnosis admission but died within 120 days from diagnosis) and 
Group 3 (58%, n = 678) (died thereafter) (21). As expected, Group 
1 who had higher severity of illness burden and older patients 
tend to have higher hospital utilization. Group 1 comprised a 
greater proportion of patients aged over 75  years (p =  0.015), 
more patients with multifocal tumor (p = 0.001), and with more 
comorbidities (p = 0.001). These patients (Group 1) have higher 
total bed days per patient (p < 0.001), greater emergency depart-
ment use (p = 0.001), greater ICU use (p = 0.001) and lower rates 
of resection (p < 0.001) (21). Another study demonstrated that 
in a subgroup of GBM patients, a home care neuro-oncological 
program, which included palliative ACP, significantly reduced 
hospital readmissions rates and ICU utilization in last 2 months 
of life compared to their counterparts without this service (16.7 
vs. 38%, respectively; p < 0.001) (30). Furthermore, there was a 
significant difference in cost for the care delivered during hospital 
stays ($9990 vs. $76,000; p < 0.001) (30).
None of the studies assessed mortality outcomes associated 
with ACP, for example, whether or not ACP was associated with 
a difference in mortality rates in pmBT patients.
DiSCUSSiON
This systematic review provides an evidence-based overview 
of ACP in pmBT patients, assimilating published literature for 
currently available evidence by including both quantitative and 
qualitative studies. The review highlights the lack of robust, meth-
odologically strong studies evaluating ACP in this population, 
with very few ACP interventions trialed to date. Due to the het-
erogeneity of the studies, best evidence synthesis was performed 
using a narrative approach. Only one RCT was found, which 
showed a positive effect in enhancing ACP information delivery 
to pmBT patients (17). The majority of the included studies in this 
review were retrospective in design, making it difficult to assess 
cause and effect of ACP interventions, and how to effectively 
conduct ACP in this population. These studies focused on EOL 
issues in pmBT patients, patterns of care, decision-making and 
palliative care support. The use of ACP also varied amongst coun-
tries with the lack of consistency of use and not being constant 
across the various contexts of care. Despite these limitations, the 
findings suggest some beneficial effects of ACP in pmBT, which 
include dignified death, lower hospital utilization and higher 
carer satisfaction.
This review highlights various issues in this area. First, there 
were limited number of studies examining ACP discussions in 
pmBT patients (18, 25) and, hence, it is difficult to draw conclu-
sions on the existing rates of EOL discussions involving various 
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aspects of ACP in pmBT patients. The findings also suggest that 
pmBT patients’ awareness of their prognosis varies considerably, 
with 40% being unaware of it (3, 35). The rates of AD completion 
ranged largely from none to 76% of patients, varying between 
different countries (3–5, 18). Although the presence of an AD 
is aimed at improving EOL care by involving an understanding 
between physicians and family members with regards to patients’ 
wishes and patients dying more often at preferred POD with less 
caregiver burden (10), AD completion was not always found effec-
tive. Congruence with patient wishes and EOL discussions was an 
interesting outcome measure noted in this review. In Europe, 10% 
of patients earlier expressed preferences were not in accordance 
with physicians’ decisions (28). Another study also reported 
that in 40% of patients, physicians were unaware of patients’ AD 
(18). There are many factors that impact on the inefficiency of 
these ACP discussions, and processes are often ineffective due 
to poor patient–physician communication and patients’ lack 
of sufficient medical knowledge to engage in these discussions. 
Furthermore, health professionals may differ in the interpretation 
of the patient’s current preference and may not always be reflected 
in their previous AD. Regular evaluation of documented AD is, 
therefore, advisable (36), along with clear communication with 
patients and surrogate decision-makers during ACP discussions 
regarding future wishes and treatment preferences. These goals 
should be reviewed over time as they may change depending on 
illness trajectory (18).
Second, there is limited data to demonstrate the appropriate 
timing of EOL discussions in patients with pmBT. The findings 
suggest a wide degree of variation in the timing of EOL discus-
sions in pmBT patients such as hospice planning prior to death 
and resuscitation wishes (25). One study stated that 52% of 
patients were incompetent to assess their own situation in the 
last weeks of life due to cognitive disturbances, aphasia and/
or delirium (25), with another 33% of patients who had lost 
their competence during the last week of life due to reduced 
consciousness (25). With a high chance of progressive functional 
and cognitive decline in pmBT patients and given the importance 
placed on mental competence in determining their QoL (18), 
timely and early discussions regarding GOC and treatment in 
EOL phase including ACP are encouraged (9, 18, 25). This will 
allow increased patient autonomy and patients to have an active 
shared treatment decision-making process with their physicians 
and family, resulting in higher QoL, increased survival rates and 
less caregiver distress (10). Authors suggest that the most frequent 
EOL decisions within the last 4 weeks of life in pmBT patients 
tend to focus upon hydration, nutrition, steroid interruption, AD, 
and palliative sedation (3).
Third, the effect of ACP in pmBT patients and their caregivers 
on confidence, well-being, QoL, and satisfaction were surprisingly 
not avidly evaluated. On study reported that an additional inter-
vention including an ACP video had a positive impact on patients 
in preferring comfort care and avoiding CPR, with improved EOL 
decision-making (17). Studies evaluating caregivers and family 
perspectives found mixed results. One study found that although 
patient and caregivers had expressed their preferences for POD, 
the majority (68%) were not able to fulfill their preferences (5). 
For patients who died a dignified death, EOL decisions were 
more often explicitly discussed. Furthermore, caregivers were 
more satisfied with physician(s) providing EOL care (32), as they 
perceived that their loved one died a dignified death.
Place of death has also been commonly evaluated. Consistent 
with other cancer populations, most terminally ill pmBT patients 
prefer to be at home during the EOL phase (37, 38). However, 
the preferred POD may change over time and the actual POD 
may not be in line with patient’s preferences. There is a wide 
variability in POD between different countries, likely reflecting 
differences in feasibility of home care, use of hospices, different 
health models of care, and access to healthcare services, such as 
palliative care support.
Primary malignant brain tumor patients have diverse and 
fluctuating symptoms, and their needs differ from other pal-
liative patients. Management of these complex patients should 
ideally performed by practitioners with expertise in supportive 
care of terminal neurological conditions. A neuropalliative 
model is an important example of a comprehensive approach 
to ACP delivery, seeking to improve QoL of patients and 
their families, as well as to address physical, psychosocial and 
spiritual needs (39, 40). The ultimate aim is to provide better 
care to those who need it most at the appropriate time, and to 
facilitate ACP discussions. The timeliness of referral to palliative 
care continues to be of great interest to healthcare profession-
als involved in the care of pmBT patients, however, the service 
remains under-utilized or continues to be initiated sporadically 
(21, 24, 25), and often used late in the cancer trajectory. To date, 
only a limited number of studies have evaluated early palliative 
care in conjunction with standard therapies for pmBT patients 
(41). This systematic review found only one moderate quality 
study that adopted a comprehensive approach to ACP delivery, 
including a pilot program of comprehensive palliative home 
care for pmBT patients (30). Consistent with the neuropalliative 
care framework, this model focused on patient’s needs for care 
in all stages of disease, aiming to support the families, deliver 
ACP information, and was shown to reduce economic costs for 
care delivered, and rehospitalization rates (30).There were no 
other studies which directly examined the cost-effectiveness 
for treatments involving ACP and mortality outcomes in this 
population.
There are several limitations in methodology and complete-
ness of the retrieved literature. Despite the comprehensive search 
using extended range of terms to capture the relevant literature, 
the search strategy principally encompassed only cited literature. 
Furthermore, the only reference lists within the relevant articles 
was searched for other possible articles missed in electronic 
searches, this may have introduced a reference bias and may 
have missed some relevant articles, including unpublished trials. 
Finally, though the CASP approach used to appraise studies is 
a robust system for evaluating various trial-based evidence, its 
sensitivity is still debatable (42). As studies identified in this 
review were of mixed methods, CASP was appropriate tool. 
As aforementioned, pooling data for meta-analyses to make 
meaningful statements was not possible. The generalizability of 
the results is limited, due to heterogeneity in study designs, study 
settings, interventions used, participant recruitment processes, 
and outcomes measures used. Furthermore, generalizability of 
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results to different countries and healthcare systems is limited as 
studies were conducted predominantly in USA and Europe, with 
varied healthcare systems.
In conclusion, this systematic review highlights sparse 
literature and lack of high-quality studies examining ACP in 
pmBT patients. Assimilation of data from existing studies was 
difficult due to heterogeneity amongst studies and their findings. 
The gap in current research should not be interpreted as inef-
fectiveness of ACP in this population, as ACP is important for 
pmBT patients where the risk of cognitive impairment and losing 
decision-making capacity are high. Overall, this review highlights 
the increasing awareness of ACP in pmBT patients for effective 
management in illness trajectory, particularly in terminal phase. 
ACP is an important element in improving EOL care of pmBT 
patients and needs to be considered for improved and/or shared 
decision-making by patients and family, increased patient and 
family satisfaction, improved physician and patient relationship, 
and enhanced QOL of the patient. Further high quality studies, 
especially RCTs, are needed to ascertain most effective types of 
ACP interventions in HGG population, and outcome measures 
could also be potentially standardized after evaluation in con-
sensus meetings to overcome heterogeneity of study outcome 
measures.
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